SECOND AMENDMENT TO BROMFENAC LICENSE AGREEMENTBromfenac License Agreement • June 2nd, 2006 • Ista Pharmaceuticals Inc • In vitro & in vivo diagnostic substances
This Second Amendment (the “Second Amendment”) is made this 31st day of May, 2006, by and between ISTA Pharmaceuticals, Inc., a Delaware corporation (“ISTA”), and Senju Pharmaceutical Co., Ltd., a legal entity organized and existing under the laws of Japan (“SENJU”).
Yukoh Yoshida President Senju Pharmaceutical Co., Ltd. 5-8, Hiranomachi 2-chome Chuo-ku, Osaka, 541-0046 Japan Dear Mr. Yoshida:Bromfenac License Agreement • December 17th, 2009 • Ista Pharmaceuticals Inc • In vitro & in vivo diagnostic substances
In connection with our recent letter regarding changing the terms and conditions of the Bromfenac License Agreement dated March 7, 2002, and amended August 13, 2002 and May 31, 2006, this letter is to further document our mutual agreement to the following additional change.
EXHIBIT 10.45 CONFIDENTIAL PORTIONS HAVE BEEN OMITTED BASED UPON A REQUEST FOR CONFIDENTIAL TREATMENT PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934 AND HAVE BEEN SEPARATELY FILED WITH THE COMMISSION. AMENDMENT TO BROMFENAC LICENSE...Bromfenac License Agreement • April 30th, 2003 • Ista Pharmaceuticals Inc • In vitro & in vivo diagnostic substances
FOURTH AMENDMENT TO BROMFENAC LICENSE AGREEMENTBromfenac License Agreement • May 4th, 2012 • Ista Pharmaceuticals Inc • Pharmaceutical preparations
This Fourth Amendment (the “Fourth Amendment”) is made this 26 day of March, 2012 (the “Effective Date”), by and between ISTA Pharmaceuticals, Inc., a Delaware corporation (“ISTA”), and Senju Pharmaceutical Co., Ltd., a legal entity organized and existing under the laws of Japan (“Senju”);
